

Decolonization of multi-drug resistant bacteria by fecal microbiota transplantation in five pediatric patients before allogeneic hematopoietic stem cell transplantation: gut microbiota profiling, infectious and clinical outcomes

Pietro Merli,^{1*} Lorenza Putignani,^{2*} Annalisa Ruggeri,¹ Federica Del Chierico,³ Livia Gargiullo,⁴ Federica Galaverna,¹ Stefania Gaspari,¹ Daria Pagliara,¹ Alessandra Russo,³ Stefania Pane,⁵ Luisa Strocchio,¹ Mattia Algeri,¹ Francesca Rea,⁶ Erminia Francesca Romeo,⁶ Paola Bernaschi,⁷ Andrea Onetti Muda,⁸ Bruno Dallapiccola⁹ and Franco Locatelli^{1,10}

¹Department of Hematology/Oncology, Cellular and Gene Therapy, Bambino Gesù Children's Hospital; ²Unit of Parasitology and Unit of Human Microbiome, Bambino Gesù Children's Hospital; ³Unit of Human Microbiome, Bambino Gesù Children's Hospital; ⁴Unit of Immunology and Infectious Diseases, University-Hospital Pediatric Department, Bambino Gesù Children's Hospital; ⁵Unit of Parasitology, Bambino Gesù Children's Hospital; ⁶Digestive Endoscopy and Surgery Unit, Bambino Gesù Children's Hospital; ⁷Unit of Microbiology, Bambino Gesù Children's Hospital; ⁸Department of Laboratories, Bambino Gesù Children's Hospital; ⁹Scientific Directorate, Bambino Gesù Children's Hospital and ¹⁰Sapienza, University of Rome, Rome, Italy

*PM and LP contributed equally as co-first authors.

Correspondence: PIETRO MERLI - pietro.merli@opbg.net

doi:10.3324/haematol.2019.244210

Supplementary Material

Post-HSCT anti-infectious prophylaxis/treatment strategy

As per institutional policy, broad-spectrum antibiotic prophylaxis with piperacilline/tazobactam was administered when neutrophils reached a value $<500/\mu\text{l}$ and continued till sustained neutrophil engraftment after HSCT; anti-fungal agents was used, as well. In case of fever developing during aplasia, antibiotics active against bacteria isolated from stools were also administered.

MDR bacteria surveillance

Microbiological surveillance was performed through weekly cultures of stools inoculated on MacConkey medium (Biomerieux, Marcy l'Etoile, France) added by meropenem at 10 ug/ml. Identification of colonies was performed by MALDI-TOF MS.(1) Enterobacteriaceae with meropenem MIC >0.5 ug/ml were selected by Vitek 2 (Biomerieux) and confirmed by concentration gradient, according to EUCAST (www.eucast.org). Selected strains were subjected to synergy tests, modified Hodge tests (2) and real-time PCR Xpert Carba-R (Cepheid, Sunnyvale, CA, USA) to detect *bla* gene encoding for KP carbapenemase (*bla_{KPC}*), New Delhi metallo-beta-lactamase (*bla_{NDM}*), Verona imipenemase (*bla_{VIM}*), oxacillinase (*bla_{OXA-48-48-181-232}*) and imipenemase (*bla_{IMP-1}*) gene alleles.

Gut microbiota profiling

DNA from stools was manually extracted using QIAmp Fast DNA Stool mini kit (Qiagen, Germany). Bacterial libraries were obtained by amplifying V3-V4 region from 16S rRNA gene (~460 bp), following the MiSeq rRNA Amplicon Sequencing protocol (Illumina, San Diego, CA). Raw sequences were analyzed using QIIME 1.9.1 software pipeline (3) from quality check to computation of α and β diversity. Reads were clustered into Operational Taxonomic Units (OTUs) at 97% identity.

Taxonomy was assigned using UCLUST against the Greengenes 13.8 database at 97% sequence similarity.(4)

Stool samples of healthy children and adults were collected for age-matched microbiota profiling for comparison. Healthy children were recruited at primary and secondary schools through pediatricians and healthy adults were recruited among health workers and researchers of OPBG (EC Protocol N° 768.12).

Gut Microbiota ecology

Before FMT (T₀), the gut microbiota of Patient 1 was mainly composed by Enterobacteriaceae, Lachnospiraceae, *Blautia*, *Lactobacillus*, Enterococcaceae, and *Staphylococcus*. At day 1 T₁ after FMT, Enterobacteriaceae increased, colonizing up to 72% of the entire microbiota composition (**Figure 2**). At day 7 (T₃), donor species, such as *Parabacteroides*, *Dorea*, *Bacteroides*, Ruminococcaceae appeared in the microbiota of the recipient, while Enterobacteriaceae, *Lactobacillus* and Enterococcaceae were strongly reduced. Alpha diversity analysis confirmed a low bacterial richness at points T₀ and T₁ compared to the donor and to the T₃ point (**Figure 2**). In addition, beta diversity PCoA plot showed similarity between T₀ and T₁ and between UD and T₃, the latter resulting closer to the CTRL group (**supplementary Figure 1**).

The gut microbiota composition of Patient 2 at day 3 (T₂) from FMT resembled the microbiota of UD for the presence of Lachnospiraceae, Ruminococcaceae, *Faecalibacterium prausnitzii*, *Bacteroides*, and *Dorea*. Furthermore, the recipient sample was also composed of *Akkermansia muciniphila* and Enterobacteriaceae. At day 7 (T₃), a reduction of Enterobacteriaceae and *A. muciniphila* and an increment of *Bacteroides fragilis* were found, with a consequent reduction of microbiota richness compared to UD and T₃ recipient samples. At day 10 (T₄), Ruminococcaceae and *F. prausnitzii* increased to 20% and 38%, respectively, resulting in an increased bacterial richness. Beta diversity

analyses showed a microbiota similarity for samples of UD, T₂, T₃ and T₄ patient time points (**supplementary Figure 1**).

On subsequent follow-up, points T₅ (day 18), and T₆ (day 25) showed a marked distance compared to the donor and to T₂, T₃ and T₄ points, while T₇ appeared separated from the entire sample set. Alpha diversity analyses highlighted an increasing richness, starting from T₅ to T₇, the latter being the highest in the sample group.

At T₃ after FMT, more than 80% of the entire gut microbiota of Patient 3 was composed by Enterobacteriaceae, Lachnospiraceae, Ruminococcaceae, *Ruminococcus*, *Dorea*, *Collinsella aerofaciens*, *Dialister*, *Bifidobacterium longum*, Clostridiaceae, *Ruminococcus gnavus*, and *Eggerthella lenta*. The alpha diversity value was similar to the donor value (**Figure 2**). The beta diversity disclosed a short distance of the T₃ sample from UD and pediatric CTRL group (**supplementary Figure 1**). The absence of T₀ and following time-point samples does not allow to get more detailed information on the shaping of microbiota after FMT.






The gut microbiota of Patient 4, at T₀ was mainly composed of Lachnospiraceae, *Oscillospira*, *Bacteroides* and *B. ovatus*. After FMT (T₁), *Bacteroides*, *B. ovatus* and Enterobacteriaceae grew up. At T₃, Bacteroidetes phylum composed the 79% of the microbiota, while at T₄, the Bacteroidetes/Firmicutes ratio was inverted. At T₅, *A. muciniphila* increased, reaching the 20% of gut microbiota composition. Points T₆ and T₇ were proximate. Microbiota richness decreased from T₀ to T₁ and then slowly increased to T₇, the highest value observed within the entire set, a pattern similar to the UD value (**Figure 2**). Beta diversity showed short distance between samples, and a shorter distance among UD and T₃, T₄, T₅, T₆ and T₇, compared to T₀ and T₁ (**supplementary Figure 1**).

The 97% of gut microbiota of Patient 5 at T₀ was composed of Enterobacteriaceae. The day after FMT, Enterobacteriaceae lowered to the 86% of entire microbiota composition. After a month (T₇), Enterobacteriaceae increased to 99% of the microbiota. The Shannon indexes were lower compared to UD, decreasing over time (**Figure 2**). Beta diversity PCoA plot revealed a close distance between

T₀, T₁ and T₇ points, and a close distance between UD and adult CTRL group (**supplementary Figure 1**).

References

1. Seng P, Drancourt M, Gouriet F, et al. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *Clin Infect Dis*. 2009;49(4):543-551.
2. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. *MMWR Morbidity and mortality weekly report*. 2009;58(10):256-260.
3. Caporaso JG, Kuczynski J, Stombaugh J, et al. QIIME allows analysis of high-throughput community sequencing data. *Nat Methods*. 2010;7(5):335-336.
4. Edgar RC. Search and clustering orders of magnitude faster than BLAST. *Bioinformatics*. 2010;26(19):2460-2461.



Supplementary Figure 1. Beta diversity of P1-P5 patients represented by PCoA plots. The PCoA plots report the beta diversity distant values for each patient time-point, UD and control groups (red circle, adult CTRL, blue circle, paediatric CTRL), calculated by Unweighted Unfrac metric.